Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31748855 | 0.83 | ADORA2A (0.47) | GRM5ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL31748885 | 0.81 | GRM5 (0.42) | GRM5ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL30717671 | 0.80 | GRM5 (0.52) | GRM5ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL30717375 | 0.77 | GRM5 (0.42) | GRM5ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL30717409 | 0.77 | GRM5 (0.42) | GRM5ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL30717359 | 0.77 | GRM5 (0.45) | GRM5ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL30717555 | 0.76 | GRM5 (0.44) | GRM5ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL30717403 | 0.76 | GRM5 (0.44) | GRM5ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL30790956 | 0.75 | ADORA2A (0.44) | GRM5ADORA2AADORA1SMYD3ALDH1A1 | |
| SCHEMBL30717397 | 0.75 | ADORA2A (0.42) | GRM5ADORA2AADORA1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2025-12-25 | — | — | US | disclosed |
| EP-4572762-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024038128-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2024-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | GRM5 2029/4885ADORA2A 67/4885ADORA1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.